Abstract
While Americans are deeply concerned about drug prices, the United States Trade Representative (USTR) continues to negotiate agreements like the United States-Mexico-Canada Agreement (USMCA) that put at risk the sustainability of the generics industry and undermine the development of biosimilars that play a critical role in access to medicines. It is time to restore some balance to US trade policy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have